Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis von Kozma, Chris M, Dickson, Michael, Phillips, Amy L, Meletiche, Dennis M

Volltext

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature von Lizán, Luis, Comellas, Marta, Paz, Silvia, Poveda, José Luis, Meletiche, Dennis M, Polanco, Carlos

Volltext

Quality-of-Life Differences Between Patients With Episodic and Transformed Migraine von Meletiche, Dennis M., Lofland, Jennifer H., Young, William B.

Volltext

PND23 PREVALENCE OF TREATMENT GAPS IN MULTIPLE SCLEROSIS PATIENTS RECEIVING DISEASE-MODIFYING DRUGS: FINDINGS FROM A NATIONAL MANAGED CARE DATABASE von Fincher, C, Kozma, C, Meletiche, DM, Dickson, M

Volltext

PND6 COMPARISON OF COSTS FOR INTERFERON BETA 1-A AND NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS von Kozma, C, Dickson, M, Meletiche, DM

Volltext

PND21 FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS von Meletiche, DM, Kozma, C, Dickson, M

Volltext

PND22 COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS PATIENTS von Meletiche, DM, Kozma, C, Dickson, M

Volltext

PND19 IMPACT OF MEDICATION ADHERENCE TO DISEASE-MODIFYING DRUGS ON SEVERE RELAPSE, AND DIRECT AND INDIRECT COSTS AMONG EMPLOYEES WITH MULTIPLE SCLEROSIS von Ivanova, JI, Phillips, AL, Bergman, RE, Birnbaum, HG, Stewart, M, Meletiche, DM

Volltext

PMH21 HEALTH CARE RESOURCE UTILIZATION AND COST OF BIPOLAR I DISORDER WITH AND WITHOUT PSYCHOTIC SYMPTOMS von Poston, S, Kozma, C, Meletiche, DM

Volltext

PDB17 AN EVALUATION OF EXPECTED WASTE OF GROWTH HORMONE PEN DEVICES AND AN ELECTRONIC GROWTH HORMONE DELIVERY DEVICE von Edwards, NC, Phillips, AL, Kreher, NC, Meletiche, DM

Volltext

PMH44: UTILIZATION AND COST OF ATYPICAL ANTIPSYCHOTICS IN MEDICAID PATIENTS WITH DEPRESSION von Markowitz, J, Meletiche, DM

Volltext

PMH9 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF ACUTE MANIA von Meletiche, DM, Meyer, K, Franklin, M, Poston, S, Grogg, A

Volltext

ND3 MODELING TREATING MULTIPLE SCLEROSISWITH DISEASE MODIFYING DRUGS USING DISCRETE EVENT SIMULATION von Guo, S, Copur, D, Ward, A, Bennett, R, Al-Sabbah, A, Meletiche, DM, Caro, JJ

Volltext

TRANSLATING SF‐36 SCORES INTO PREFERENCES: AN EXAMINATION OF THE PERFORMANCE OF TWO PREDICTIVE EQUATIONS von Meletiche, Dm, Roberts, Cs, Lofland, Jh

Volltext

PND12 MODELING THE CLINICAL AND ECONOMIC CONSEQUENCES OF TREATING RELAPSING FORM OF MULTIPLE SCLEROSIS WITH SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON-BETA-IA von Guo, S, Copur, D, Ward, A, O'Brien, JA, Ishak, KJ, Bennett, R, Al-Sabbah, A, Meletiche, DM, Caro, JJ

Volltext

PMH53: IMPACT OF WEIGHT GAIN ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF BIPOLAR PATIENTS von Bolge, SC, Meletiche, DM

Volltext

Medical outcomes study short form 36: A possible source of utilities? von Meletiche, Dennis M., Doshi, Dilesh, Lofland, Jennifer H.

Volltext

PMH18 UTILIZATION AND COST OF RESOURCES IN BIPOLAR PATIENTS RECEIVING ATYPICAL ANTIPSYCHOTICS von Meletiche, DM, Bolge, SC, Lasser, R

Volltext

PMA18: THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES von Bakst, A, Meletiche, DM, Arnold, R, Harjono, H, Najib, M, Cobitz, A

Volltext

THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®): AN INTERNET‐BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES von Bakst, A, Meletiche, Dm, Arnold, R, Harjono, H, Najib, M, Cobitz, A

Volltext